Blood Trail

Electrovore · 2019 · $24.99 · Action · deal grade A

Estimated net residual revenue: $12.7k to $19.0k per month
Opportunity: $21.4k per month at x1.35 dormancy
Estimated lifetime owners: 285.2k
80%% positive across 7580 reviews · 118.0 reviews/month

Why it's flagged

Developer silent for 15 months
Studio quiet across its whole catalog
Last build shipped 15 months ago
Store page localized in only 1 language(s)
Last discounted 1 months ago, 4 sales in the last 12 months

Analyst notes (AI-assisted)

Blood Trail is a VR action sandbox built on impressive physics and gore mechanics, dormant since May 2025 with $15.8k/mo residual revenue.

Blood Trail generates solid monthly residual income ($15.8k/mo mid-estimate) and maintains 80% positive reviews despite 15+ months without developer communication. The core gameplay loop (physics, gunplay, melee) resonates strongly with players who compare it favorably to Blade and Sorcery. However, Electrovore's studio status is fading, the title is stuck in early access after 7 years, and the developer has zero public footprint. This is a acquisition target for a VR-focused publisher or studio willing to invest in polish, content, and community rebuilding; revival is viable only if IP ownership can be secured cleanly. Most realistic play: acquisition.

Risk: Game has been in early access for 7 years with physics-heavy codebase; modernizing engine or fixing legacy bugs (aim issues, crashes, calibration) may require substantial engineering investment.
Risk: Developer has been radio-silent for 15 months; unclear if Electrovore is unreachable, defunct, or in dispute; acquisition due diligence on IP chain and underlying contractual obligations is critical.
Risk: VR market remains niche and price-sensitive; $24.99 is at ceiling for early-access sandbox titles; player churn risk is high without meaningful content pipeline post-acquisition.

This case as Markdown · Estimates carry ±30-50%% error per title.